

Overview of CML related sessions at 23rd EHA Meeting in Stockholm

Time slots	Sessions	Location
June 14th (Thursday)		
8.00 – 10.00	<p>Satellite Symposium: Targeting the individual: Personalized treatment in CML (Supported by Pfizer Oncology)</p> <p>Chair:</p> <ul style="list-style-type: none"> • Prof. R Clark (Royal Liverpool University Hospital, UK) <p>Program:</p> <ul style="list-style-type: none"> • Introduction (R Clark) • A new option in the treatment of first-line CML (M Deininger) • A wealth of choices in first-line CML: how to choose the right TKI in first line (R Clark) • Treatment options in second-line and beyond: A case-based discussion (D Wolf) • Chronic treatment vs. cure: future challenges in CML treatment (H Hjort-Hansen) • Q&A (R. Clark) 	Room A2
10.45 – 12.45	<p>Satellite Symposium: Recent advances in CML and MPN's (Supported by Novartis Oncology)</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Prof. A Hochhaus (University Hospital Jena, Germany) • Dr J Samuelsson (Stockholm South Hospital, Sweden) <p>Program:</p> <ul style="list-style-type: none"> • Welcome (S. Samuelsson) 	Room A1

Time slots	Sessions	Location
	<ul style="list-style-type: none"> • Current treatment landscape in CML (TP Hughes) • Current treatment landscape in classical MPN (RA Mesa) • Challenges and future perspectives in CML (JE Cortes) • Challenges and future perspectives in classical MPN's (AM Vannucchi) • Summary and Q&A (A Hochhaus) 	
10.45 – 12.45	<p>Satellite Symposium: Immuno-oncology in haematologic malignancies: The evolving biomarker story (Supported by Bristol Myers Squibb)</p> <p>Chair: Dr O Landgren (Memorial Sloan Kettering Cancer Center, New York, USA)</p> <p>Program:</p> <ul style="list-style-type: none"> • Insights and current perspectives: An Introduction to I-O advances and biomarker research (O. Landgren) • Gaining an understanding of the relationship between the tumor and the tumor microenvironment (B Paiva) • The individualized approach: Personalizing medicine through biomarkers (A Diepstra) • Evolving bench to bedside and back: Designing biology-driven studies (N Daver) 	Room A2
19.00 – 21.00	<p>Satellite Symposium: Planning your next move in Ph+ leukaemias (Supported by Incyte)</p> <p>Chair: H Hjort-Hansen (Institute of Cancer Research and Molecular Medicine (IKM) Norwegian University of Science and Technology (NTNU), Trondheim, Norway)</p> <p>Program:</p> <ul style="list-style-type: none"> • Screening and monitoring approaches to optimise treatment in Ph+ leukaemias (S Soverini) • Screening and monitoring approaches to optimise treatment in Ph+ leukaemias (T Lion) 	

Time slots	Sessions	Location
	<ul style="list-style-type: none"> Panel discussion (H Hjorth-Hansen) Evolving strategies for the management of Ph+ ALL (Part 1) (C Junghanß) Evolving strategies for the management of PH+ ALL (Part 2) (R Bassan) Panel discussion and summary (H Hjorth-Hansen) 	
June 15th (Friday)		
14.30 – 15.30	Meet-the-expert: Treatment options in resistant CML patients Speaker: Prof. J Apperley	Room A12
17.30 – 19.00	Poster Session: Chronic myeloid leukemia – Biology and translational research Program: <ul style="list-style-type: none"> (PF359): Inhibition of nucleocytoplasmic export enhances selective elimination of leukemic stem cells in chronic myeloid leukemia (M Deininger) (PF360): Immunomodulatory effects of IFN-alpha on T- and NK-cells in chronic myeloid leukemia patients in deep molecular response identify potential candidates for treatment discontinuation (M Breccia) (PF361): Identification of genes differently expressed between bone marrow CD34+LIN cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment (R Cairoli) (PF362): NK-cells and loss of molecular response after TKI discontinuation in CML patients (N Kapranov) (PF363): LMC-trio, a real life study of chronic myeloid leukemia care in France between 2006 and 2013: Factors of failure from treatment-free remission (C Jim) (PF364): Polymorphisms in multi-drug resistance transporter genes affect the duration of molecular response to nilotinib in chronic myeloid leukemia patients (F Loscocco) 	Poster area

Time slots	Sessions	Location
	<ul style="list-style-type: none"> (PF365): Myeloid cell population dynamics in TKI-treated CML (S Sopper) (PF366): The effect of pregnane X receptor SNP and TKI through concentration on clinic response and toxicity among Chinese CML patients (Z Jiang) (PF367): WT1 expression predicts the responsiveness of chronic myeloid leukemia to first-line therapy of tyrosine kinase inhibitor (E Toffoletti) 	
June 16th (Saturday)		
8.00 – 9.30	<p>Patient Advocacy Session 1: QoL – Why still an inconsistent path to an obvious goal?</p> <p>Chairs:</p> <ul style="list-style-type: none"> L Brunetta (Thalassaemia International Federation, Genoa, Italy) S Wintrich (MDS UK Patient Support Group, London, UK) <p>Program:</p> <ul style="list-style-type: none"> Introduction: Is quality of life a priority in treatment today? A patient perspective (A Bok) Quality of life during and after treatment (H Kaur) Treatment at home for haematological patients: Safe, feasible – and improving patient experience? (L Kjelden) The impact of cancer and its treatment on sex life (A Plate) From frail to fit: The importance of pre-rehabilitation and rehabilitation on QoL (N Bolaños) 	Room K21
9.45 – 10.45	<p>Scientific Working Group (SWG): Chronic myeloid leukemia – ELN-EHA SWG session on CML 2018</p> <p>Chair:</p> <ul style="list-style-type: none"> Prof. R Hehlmann (ELN Foundation, Weinheim, Germany) 	Room A8

Time slots	Sessions	Location
	<p>Program:</p> <ul style="list-style-type: none"> • The relevance of cytogenetics in the course of CML (C Haferlach) • Does IFN improve outcome of CML in the imatinib era? (FE Nicolini) • Worldwide standardization of BCR-ABL monitoring (N Cross) • End results of the EUTOS-registry project (M Baccarani) 	
11.30 – 12.45	<p>Oral Presentation: CML and MPN – Clinical</p> <p>Chairs:</p> <ul style="list-style-type: none"> • H Hjorth-Hansen (Institute of Cancer Research and Molecular Medicine (IKM) Norwegian University of Science and Technology (NTNU), Trondheim, Norway) • S Koschmieder (RWTH Aachen University, Germany) <p>Program:</p> <ul style="list-style-type: none"> • (S809): Final results of the DESTINY Study of de-escalation and stopping treatment in chronic myeloid leukaemia (R Clark) • (S810): CHOISES: A randomized phase II trial for imatinib vs hydroxychloroquine plus IM for patients with CML in MCYR with residual disease detectable by q-BCR (GA Horne) • (S811) The EUTOS long-term survival (ELTS) score is superior to the SOKAL score for prognosis of survival probabilities of patients with chronic-phase chronic myeloid leukaemia (M Pfirrmann) • (S812): Phase II study of ruxolitinib in combination with 5-azacitadine in patients with myelofibrosis (L Masarova) • (S813): Establishment of a simple risk score to predict systematic mastocytosis (SM) in adult patients with mastocytosis in the skin (MIS) (D Fuchs) 	Room A2

Time slots	Sessions	Location
11.30 – 12.45	<p>Patient Advocacy Session 2: Not only survival: Patient-reported endpoints and patient-reported outcomes</p> <p>Chairs:</p> <ul style="list-style-type: none"> • J Geissler (CML Advocates Network, Munich, Germany) • M Piggin (PNH Support, London, UK) <p>Program:</p> <ul style="list-style-type: none"> • Are study endpoints like OS and PFS most relevant to patients and describe highest patient value? (J Geissler) • Meaningful patient-reported outcomes – How to learn from real-life experience in clinical research (G Garcia-Manero) • The end of huge questionnaires? Innovative electronic PRO measurement tools (H Kaur) • Q&A panel discussion (J Geissler, G Garcia-Manero, H Kaur) 	Room K21
14.45 – 15.45	<p>Advocacy Session: EU projects in hematology: HARMONY: Big data and big data analytics: To enable better and faster treatment for patients with hematologic malignancies</p> <p>Chair: JM Hernández</p> <p>Program:</p> <ul style="list-style-type: none"> • Welcome and introduction (P Sonneveld) • HARMONY: First year achievements (G Sanz & P Bacon) • Data management and analytics of the HARMONY data platform (M van Speybroeck & R Villoria) • Legal aspects of data protection in HARMONY (J Butler) • HARMONY: Unlocking valuable knowledge: Overview of “Bench-to-bedside” Pilot projects (L Bulling & A Taylor) 	Room K2

Time slots	Sessions	Location
	<ul style="list-style-type: none"> AML: Leading the way: the first results (H Döhner & S Mendelson) Update of the MM ad APL projects (P Ghia) Wrap up & Invitation to become a data provider (JM Hernández) 	
16.00 – 17.15	<p>EHA Advocacy Session: The real-world value of new generation treatments</p> <p>Chair: O Ottoman (Cardiff University, UK)</p> <p>Program:</p> <ul style="list-style-type: none"> What does the real world look like? The patient perspective (M Piggin) The use of patient reported outcome measures (PROMs) to drive patient interests: an ICHOM perspective (M Ingvar) Good decisions need good data: an HTA perspective (S Lange) 	Room K21
17.30 – 19.00	<p>Update in Hematology: Biosimilars in Hematology – Plotting the course to long-term sustainability (Supported by Sandoz)</p> <p>Chair:</p> <ul style="list-style-type: none"> Dr PC Cornes (Comparative Outcomes Group, Bristol, UK) <p>Program:</p> <ul style="list-style-type: none"> Introduction and welcome (PC Cornes) A patient's journey: A life without biosimilars (S Scowcroft) Why we need biosimilars: Mapping out a path to sustainable care (P Cornes) A patient's journey: A life with biosimilars (S Scowcroft) Panel speaks: Navigating the totality of evidence for rituximab biosimilars: how much and which data are necessary? (AG Vulto) A patient's journey: Does extrapolation matter? (S Scowcroft) Panel speaks: Driving data extrapolation in hematologic malignancies: 	Room A7

Time slots	Sessions	Location
	<p>Key considerations for clinical practice (C Buske)</p> <ul style="list-style-type: none"> Ask the faculty and closing remarks (P Cornes) 	
17.30 – 19.00	<p>Poster Session: Chronic myeloid leukemia – Biology and Translational Research</p> <p>Program:</p> <ul style="list-style-type: none"> (PS1109): Enrichment of ASXL1 pathogenic variants among primary refractory CML patients (C Ayoola Gustafsson) (PS1110): The pivotal role of insulin-like growth factor pathway as a therapeutic target in ABL tyrosine kinase inhibitor resistant leukemia cells (S Okabe) (PS1111): ASXL1 mutations are frequent in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors but not in patients with optimal response (M Machnicki) (PS1112): The uncovering of BCR-ABL1 tyrosine kinase-independent signature reveals new potential therapeutic targets in chronic myeloid leukemia stem cells (E Gomez-Castaneda) (PS1113): Optimal time point for BCR-ABL1 KD mutation analysis in CML patients; based on 2013 ELN guideline (Y Rock Do) (PS1114): Clonal selection determines resultant dominance of tyrosine kinase inhibitor-resistant cells in chronic myeloid leukemia (B Leow) (PS1115): WT1 analysis in chronic myeloid leukemia (CML) patients (S Coluzzi) (PS1116): Digital droplet PCR may better identify candidates for treatment discontinuation in chronic myeloid leukemia regardless of median treatment duration (G Colafigli) (PS1117): Frequency of typical and atypical fusion transcripts in patients with BCR-ABL1-positive leukemias – a single institution study (G Balatzenko) 	Poster area
17.30-19.00	Poster Session: Chronic myeloid leukemia – Clinical	

Time slots	Sessions	Location
	<p>Program:</p> <ul style="list-style-type: none"> • (PS1118): Patient-specific BCR-ABL1 genomic fusion analysis of minimal residual disease of CML patients eligible for TKI stopping significantly outperformed MRNA detection either by qPCR or digital PCR (K Machova-Polakova) • (PS1119): Treatment-free remission after second-stop of imatinib patients with chronic myeloid leukemia in chronic phase (S Oh) • (PS1120): Two years of therapy with imatinib generics in chronic myeloid leukemia; a report from the Polish Adult Leukemia Group (PALG) imatinib generics registry (T Sacha) • (PS1121): Maintenance therapy with imatinib administrated every other day in patients with chronic myeloid leukemia (C. Loiseau) • (PS1122): Ponatinib 15 mg daily, combining efficacy and tolerability. A retrospective survey in Italy (G Binotto) • (PS1123): The EUTOS long-term survival predicts response and survival of elderly chronic myeloid leukemia patients better than SOKOL score (F Castagnetti) • (PS1124): Cardiovascular toxicity in chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors in real-life practice. Identification of risk factors and role of prophylaxis (G Caocci) • (PS1125): Ultra-sensitive detection of tyrosine kinase inhibitor resistant mutations in chronic myeloid leukemia patients using Miseq Illumina next generation sequencing platform (M Romzova) • (PS1126): Peg-interferon alpha 2B can improve molecular recurrences in the treatment-free remission; a pilot study with 18-months follow-up (M Ayala) • (PS1127): Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors in patients with Philadelphia chromosome-positive leukemia: Phase 1/2 study update (J Cortes) • (PS1128): Chronic myeloid leukemia Italian multicenter observational study (CML-IT- 	

Time slots	Sessions	Location
	<p>MOS): Analysis of clinical characteristics of 1130 CML patients treated in real-life in 66 Italian centers of the GIMEMA Group (G Speccia)</p> <ul style="list-style-type: none"> (PS1129): Imatinib STOP study feasible to Japanese clinical setting (K Usuki) (PS1130): The TARGET UK Study: An evaluation of tyrosine kinase inhibitor response monitoring patterns and real-world molecular response rates in UK patients with chronic myeloid leukaemia (A Mead) 	
June 17th (Sunday)		
8.00 – 9.15	<p>Oral Presentation: CML and MPN – Biology</p> <p>Chair: O Hantschel (Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland)</p> <p>Program:</p> <ul style="list-style-type: none"> (S1550): The tumor suppressor MIR-300 preserves cancer stem cells and inhibits NK cell anticancer immunity (D Perrotti) (S1151): JAK1 STAT3 signaling axis supports leukemic stem cell persistence in CML (M Schemionek) (S1152): MS4A3 regulates cell surface cytokine receptor expression, differentiation, and drug resistance in chronic myeloid leukemia (A Eiring) (S1153): The combination of the MDM2 antagonist, idasanutlin with nilotinib targets primitive chronic myeloid leukemia (CML) cells in vitro and in vivo (M Scott) (S1154): The mutational landscape in hydroxycarbamide-resistant/intolerant essential thrombocythemia treated on the MAJIC-ET Study (J O' Sullivan) 	Room A2

Time slots	Sessions	Location
9.30 – 11.00	Education Session: Chronic myeloid leukemia Chair: Prof. S. Saußeke (Universitätsklinikum Mannheim, Germany) Program: <ul style="list-style-type: none"> • Single cell genomics in CML (A Mead) • Immune targeting of CML to improve treatment outcome (A Burchert) • TFR treatment goal for all CML patients (D Rea) 	Room K1
11.15 – 12.45	Education Session: Chronic myeloid leukemia Chair: Prof. S. Saußeke (Universitätsklinikum Mannheim, Germany) Program: <ul style="list-style-type: none"> • Single cell genomics in CML (A Mead) • Immune targeting of CML to improve treatment outcome (A Burchert) • TFR treatment goal for all CML patients (D Rea) 	Room K1